Madrigal Pharmaceuticals, Inc.
NASDAQMDGL short interest plunged 41% over one week to 8.6% of float, as shorts exited ahead of earnings. Availability surged to 1,409%, signaling minimal squeeze risk.
Madrigal Pharmaceuticals reports Q2 results tomorrow with the most striking pre-earnings positioning shift of the season: short sellers have cut their exposure nearly in half over 30 days, while two fresh analyst…
Madrigal Pharmaceuticals heads into Wednesday's Q2 earnings report with short sellers having dramatically reduced their exposure over the past month — the starkest positioning shift heading into this print. The retreat…
Snapshot as of 6 Aug 2026
MDGL heads into its June 17 earnings date with short sellers in modest retreat and a cost-to-borrow that just doubled in a single session, creating a quietly charged setup for a stock that has barely moved in a…
Madrigal Pharmaceuticals heads into the post-earnings stretch with short sellers retreating and the Street turning incrementally more constructive — the tension being that even after a 6.4% earnings-day pop, shorts…
Madrigal Pharmaceuticals posted Q1 2026 results today that landed above expectations on both lines — yet the stock fell 3% on the session to close at $502.47, and is down nearly 9% over the past month. The disconnect…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MDGL — free to start on ORTEX.
Sign up for free →Open MDGL on ORTEX